Sarepta Therapeutics (SRPT) Q1 2025: Alevitus Revenue Jumps 180% but Guidance Cut on Cycle Delays

2025-05-06 | By EarningsIQ Research

Sarepta’s Q1 saw Alevitus, its gene therapy for Duchenne muscular dystrophy (DMD), deliver historic patient reach and 180% revenue growth, but operational friction and a safety event forced a guidance cut. Management now projects a revenue rebound in the second half, hinging on physician education and site expansion. Investors must weigh robust long-term demand signals against near-term execution and uptake risks.

Summary

• Gene Therapy Uptake Disrupted: Administrative complexity and a tragic safety event delayed infusions, driving a guidance reduction.
• Site Capacity Imbalance: Leading centers are fully booked, requiring urgent focus on activating underutilized secondary sites.
• Second-Half Recovery Bet: Management expects demand and infusions to accelerate as education and site engagement ramp up.

Performance Analysis

Sarepta delivered 70% year-over-year net product revenue growth in Q1, propelled by a 180% surge in Alevitus sales, its gene therapy for DMD. The PMO (phosphorodiamidate morpholino oligomer, antisense oligonucleotide-based therapies) franchise grew 5%, maintaining its $900 million run-rate target for the year. However, the quarter fell short of expectations due to multiple headwinds: a severe flu season, a high-profile patient death after Alevitus infusion, and persistent administrative bottlenecks in the gene therapy pathway.

Revenue guidance was cut to $2.3 billion to $2.6 billion (midpoint still up 37% YoY), reflecting the impact of longer cycle times (now 4-6 weeks longer than initial estimates), temporary demand softening, and the need to shift focus to less-utilized infusion sites. Q2 revenue is expected to be up to 20% below Q1 before a projected second-half recovery.

• Gene Therapy Revenue Concentration: 60% of Alevitus sales came from top-tier centers, many now booked out for 12 months, limiting near-term growth.
• Administrative Drag: Delays in insurance (notably a Medi-Cal issue), screening, and single-case agreements extended time-to-infusion, impacting revenue recognition.
• Temporary Demand Pause: The safety event led some families to delay treatment, though management reports that informed physicians remain confident in Alevitus’s risk-benefit profile.

Operating loss was driven by a one-time $584 million Arrowhead collaboration charge, but underlying cash flow and balance sheet remain robust, supporting ongoing R&D and capital allocation flexibility.

Executive Commentary

Strategic Positioning

1. Gene Therapy Launch Dynamics

Alevitus remains the first and only broadly approved disease-modifying gene therapy for DMD, offering the potential to arrest muscle damage in over 80% of patients. Despite this, uptake is constrained by administrative complexity, physician education gaps, and site capacity imbalances. Sarepta’s “Sarepta Exchange” program, which connects physicians to expert peers in real time, is a strategic lever to standardize outcomes and support broader adoption.

2. Site Network Optimization

Revenue is heavily concentrated in leading academic centers, which are now at or near full capacity. Management is pivoting to activate secondary and community sites, providing high-touch support and education to unlock latent capacity. Success here will be critical to sustaining growth and meeting revised guidance.

3. Lifecycle Expansion and Pipeline Progress

The Alevitus lifecycle development continues with the Envision trial (Phase III in older and non-ambulatory DMD), post-marketing studies, and efforts to expand access for antibody-positive patients. Sarepta’s LGMD (limb-girdle muscular dystrophy) gene therapy programs are advancing through pivotal stages, leveraging shared AAV vector technology. The siRNA platform is also progressing, with key data readouts expected in the second half of the year.

4. Commercial Model Adaptation

One-time gene therapy launches require a fundamentally different commercial model than chronic therapies. Small delays in a handful of patients can materially impact quarterly revenue, amplifying the importance of operational execution, payer navigation, and patient journey management.

Key Considerations

This quarter’s reset highlights the operational realities of launching a transformative, one-time therapy in a rare disease setting. The path from regulatory approval to broad patient access is non-linear, and investor focus must shift from headline growth to the mechanics of sustainable uptake.

Key Considerations:

• Cycle Time Sensitivity: Each additional week from start form to infusion directly impacts quarterly revenue in a one-time therapy model.
• Physician and Family Education: Misinformation or incomplete safety context can delay uptake; robust communication is required to maintain momentum.
• Site Activation Leverage: Unlocking capacity at underutilized centers is now the gating factor for growth, not payer access or total site count.
• Pipeline Optionality: Progress in LGMD and siRNA programs provides diversification and future revenue drivers as Alevitus matures.

Risks

Execution risk is elevated: delays in patient education, site ramp, or further adverse events could prolong the revenue trough. Regulatory risk is present as the FDA reviews the updated Alevitus label following the safety event, though management and clinical data suggest no new safety signal. Competitive gene therapy programs and payer policy shifts also warrant close monitoring, but current access rates remain high.

Forward Outlook

For Q2, Sarepta guided to:

• Revenue up to 20% below Q1, reflecting the lag from paused infusions and ongoing site ramp.

For full-year 2025, management revised guidance to:

• Total net product revenue of $2.3 billion to $2.6 billion (all reduction from Alevitus, PMO guidance unchanged at $900 million).

Management highlighted several factors that will drive the second-half recovery:

• Expanded education and outreach to both physician and patient communities.
• Activation and support of secondary sites to relieve bottlenecks at leading centers.
• Continued payer access with 100% success rate to date for Alevitus.

Takeaways

The Q1 reset underscores that transformative therapies require transformative execution—and that operational friction can outweigh even historic demand. Sarepta’s long-term DMD opportunity remains intact, but the near-term path is more volatile than initially modeled.

• Revenue Timing Risk: Cycle delays and site imbalances, not market size or payer access, are the primary barriers to growth in 2025.
• Education Drives Uptake: Physician and family confidence in Alevitus’s risk-benefit profile is critical to unlocking pent-up demand, especially after a safety event.
• Pipeline Remains a Hedge: LGMD and siRNA programs could provide upside as commercial Alevitus matures and execution stabilizes.

Conclusion

Sarepta’s Q1 2025 was a case study in the operational complexity of gene therapy launches—with robust demand signals overshadowed by administrative and educational headwinds. The company’s ability to pivot and unlock site capacity will determine if second-half momentum materializes as projected.

Industry Read-Through

Sarepta’s experience is a stark reminder for the gene therapy sector: even with strong clinical data and payer access, commercial inflection is gated by operational execution—especially in rare diseases with complex patient journeys. Delayed infusions, site bottlenecks, and the outsized revenue impact of one-time therapies are likely to affect other gene therapy launches. Investors should scrutinize not just demand signals, but also the company’s ability to educate, activate, and support a broad network of treatment sites. The sector’s valuation will increasingly hinge on execution, not just innovation.

SRPT Healthcare Biotechnology Gene therapy Duchenne Rare disease Pipeline